Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Lowers Price Target to $314

Benzinga · 1d ago
Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and lowers the price target from $322 to $314.